1 / 50

GASTROINTESTINAL BLEEDING

GASTROINTESTINAL BLEEDING. Ajay Jain, MD, FACG, FRCPC Gastroenterologist Meridian Medical Group INSGNA March 5, 2011. Objectives. Introduction Lower Gastrointestinal Bleeding (LGIB) etiology presentation diagnostic testing management Upper Gastrointestinal Bleeding (UGIB) etiology

keefe
Télécharger la présentation

GASTROINTESTINAL BLEEDING

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. GASTROINTESTINAL BLEEDING Ajay Jain, MD, FACG, FRCPC Gastroenterologist Meridian Medical Group INSGNA March 5, 2011

  2. Objectives • Introduction • Lower Gastrointestinal Bleeding (LGIB) • etiology • presentation • diagnostic testing • management • Upper Gastrointestinal Bleeding (UGIB) • etiology • evaluation • endoscopy • management

  3. Introduction • gastrointestinal bleeding (GIB) common clinical problem • source of GIB traditionally divided into either upper or lower • upper gastrointestinal bleeding (UGIB): • bleeding from any source proximal to ligament of Treitz • lower gastrointestinal bleeding (LGIB): • bleeding from any source distal to ligament of Treitz

  4. Lower Gastrointestinal Bleeding • one-fifth to one-third as common as UGIB • less severe course compared with UGIB • annual incidence rate: • 25 cases per 100,000 adult population at risk (UGIB rate : 150 cases per 100,000) • incidence increases with age • greater than 200-fold increase from 20s to 80s • mean age of patients with LGIB: 63 - 77 • mortality rate 2 - 4%

  5. LGIB - Etiology Age, Mortality Rates, and Causes of Acute Lower Gastrointestinal Bleeding in the Elderly NA Not available * Includes Inflammatory bowel disease, infectious colitis, radiation colitis, vasculitis and inflammation of unknown origin Ψ Expressed as % of colonic causes of bleeding

  6. LGIB - Presentation • Chief complaint may vary • passage of occasional bright red blood per rectum associated with formed, brown stool • patient usually hemodynamically stable • passage of relatively higher volumes of bright red blood (“hematochezia”) • patient may be hemodynamically unstable • passage of black, tarry stools (“melena”) • first evaluate for UGIB • if evaluation shows no upper GI source then consider bleeding from right colon or small bowel • patient may be hemodynamically unstable

  7. LGIB • Monitoring • patients may be critically ill at presentation • not only at risk for direct consequences of GI tract pathology, but also for cardiac, pulmonary, renal and neurologic complications of acute blood loss • identify symptoms of hemodynamic compromise: • postural symptoms/fatigue/palpitations/chest pain/dyspnea • monitor vital signs (including postural vitals) • increase of > 10 beats/min or drop in BPs > 10mmHg indicative of at least a 15% acute blood loss volume Ebert et al, Arch Int Med 1941; Am Coll Surg 1993

  8. LGIB • Initial resuscitation • restore euvolemia, prevent complications of acute blood loss • MI, CHF, CVA, etc. • transfuse packed red blood cells as necessary • correct coagulopathy • fresh frozen plasma & vitamin K • obtain relevant history while resuscitation is underway • duration of bleeding/presence or absence of abdominal pain/chest pain /fever • history of ulcer disease/IBD/radiation therapy to abdomen or pelvis • cardiopulmonary, renal, hepatic disease • current medications (ASA, NSAIDS, anticoagulants)

  9. LGIB • Initial resuscitation (cont’d) • Physical examination • cardiac/pulmonary/abdominal and rectal examinations • Laboratory studies • CBC/electrolytes/BUN/CR/PT/PTT • type and cross • EKG

  10. LGIB • Not All Hematochezia is Due to a Colonic Source • first think of a colonic source of bleeding but remember that UGIB source may present with hematochezia, if the bleeding is brisk • in one series 11% of patients with hematochezia and hemodynamic compromise had an UGI source Jensen et al, Gastroenterology 1988

  11. LGIB • Not All Hematochezia is Due to a Colonic Source (cont’d) • nasogastric (NG) tube is reasonable to use to evaluate for possible UGIB • note presence or absence of both blood and bile • if significant blood seen on NG tube, consider performing upper endoscopy • presence of bile confirms that duodenal contents sampled; if bile absent an upper GI endoscopy should be considered • NG tube has been shown to be useful test in this regard with accuracy of 94-98% • no role for upper GI barium x-ray Luk et al, JAMA 1979; Cuellar et al, Arch Intern Med, 1990

  12. LGIB • Sources of Colonic Bleeding • Diverticulosis • arterial bleeding, painless, ceases spontaneously in most cases

  13. LGIB • Sources of Colonic Bleeding • Diverticular Bleeding 87 year-old woman who presented with lower gastrointestinal bleeding. The bleeding was finally localized to a single diverticulum, shown here

  14. LGIB • Sources of Colonic Bleeding • Angiodysplasia • vascular malformations • frequently involves proximal colon Arrow indicates point of bleeding

  15. LGIB • Sources of Colonic Bleeding • Colonic Neoplasia (large adenoma or adenocarcinoma) • may present with blood per rectum but more often present with change in bowel habits, abdominal pain or other related symptom Sessile (flat) polyp Bleeding polyp Colon cancer

  16. LGIB • Sources of Colonic Bleeding • Inflammatory Colitides/Ulceration • inflammatory bowel disease, infectious colitis, radiation colitis, vasculitis 33 year-old man with Crohn’s colitis involving the proximal colon, with severe inflammation, edema and ulcers Normal vascular pattern Normal transverse colon

  17. LGIB • Sources of Colonic Bleeding • Anorectal • hemorrhoids, anal fissure, idiopathic rectal ulcer

  18. LGIB • Diagnostic Testing • Colonoscopy clearly test of choice • no evidence that colonic purge will increase the rate of bleeding or cause renewed bleeding if it has ceased • overall diagnostic yield of colonoscopy 70-80% • not only allows identification of bleeding source but also can apply therapy to stop bleeding • endoscopic therapies (discussed in greater detail with UGIB) • Thermal (heater probe, argon plasma coagulation) • Injection (epinephrine, ethanolamine etc.) • Mechanical (band ligation, hemoclips, endoloops) Forde et al, Gastrointest Endosc 1981

  19. LGIB • Diagnostic Testing (cont’d) • Angiogram • use if unable to find bleeding site • diagnostic yield: 40-80% • usually need to have a bleeding rate of >0.5mL/min to identify extravasation of contrast into bowel • risk of complications greater than colonoscopy • contrast-induced renal failure, contrast allergy, bleeding after arterial puncture, embolism from dislodged thrombus • therapy can be applied (embolization or intra-arterial injection) • Nuclear Medicine Red Blood Cell (RBC) Scan • can potentially identify slower rate of bleeding • diagnostic yield 26-72% Gomes et al, AJR 1986; Suzman et al, Ann Surg 1996

  20. LGIB • Role of Surgery • if bleeding does not cease, and site of bleeding known, directed surgery (ie. limited colonic resection) can be performed with better outcomes compared with subtotal colectomy or “blind” right hemicolectomy • Evaluation of Small Intestine • LGIB but no colonic source identified • rule-out UGIB first • if absent upper and lower GI source, exam small intestine: • video capsule endoscopy • enteroclysis • Meckels scan

  21. ALGORITHM TO ACUTE LGIB (Part 1) SEE NEXT SLIDE

  22. ALGORITHM TO ACUTE LGIB

  23. Upper Gastrointestinal Bleeding • can divide causes into • variceal and non-variceal UGIB (focus on non-variceal UGIB) • Healthcare burden/cost of UGIB from peptic ulcer disease • 250,000 to 300,000 hospital admissions • $2.5 billion in US each year • despite advances in diagnosis and treatment, mortality of UGIB remains from 5 – 14% • mortality higher in patients > 60 yrs and in patients with multiple comorbid conditions Rockall et al, Lancet 1995; Rockall et al, Gut 1996

  24. UGIB • Natural History • majority of patients with UGIB will spontaneously cease • 70-80% will stop within first 48 hrs of onset; of those 10-20% will have recurrence of UGIB • at initial presentation ~20% will continue to bleed • mortality greatest in these patients and also patients that have recurrent bleeding

  25. UGIB - Etiology

  26. UGIB - Etiology • 20-30% of patients will have two or more diagnoses of UGIB • no disease entity is found in 10-15% of patients (prognosis is excellent) • bleeding peptic ulcer disease most common etiology and is also the most widely studied • excellent randomized control trials regarding best treatment modalities, outcomes, risk of rebleeding and natural progression

  27. UGIB • Initial evaluation • monitor hemodynamic status • IV access; vigorous volume replacement • confirm UGI source of bleeding by • history (hematemesis – fresh blood or coffee ground emesis, melena) • nasogastric aspiration is 80% sensitive for actively bleeding UGI source • False negative aspirates occur when the tube is improperly positioned or when reflux of blood from a duodenal source prevented by pylorospasm or obstruction Cuellar et al, Arch Intern Med 1990

  28. UGIB • Endoscopy • when UGIB suspected, test of choice for identifying and treating the bleeding lesion is upper endoscopy • no role for barium studies in acute UGIB • greatest benefit in the ~20% of patients with continued or recurrent bleeding • endoscopy can improve morbidity and mortality • endoscopic therapy with coagulation and/or injection therapy effective in the setting of actively bleeding ulcers • active bleeding can be controlled in 85-90% of patients, with less than 3% complication rate • mortality decreased by nearly one third • concurrent use of proton pump inhibitors (eg. IV prevacid or protonix) of significant benefit in decreasing recurrent bleeding Sacks et al, JAMA 1990; Laine et al, Gastro 1990

  29. UGIB • Endoscopy • management decision for other 80% who will not have further bleeding can be altered by aggressive diagnosis • requires ability to separate high-risk patients from low-risk patients • clinical indicators of higher mortality from UGIB • variceal bleeding • advanced age • comorbid illnesses • large volume bleeding • persistent or recurrent bleeding despite medical therapy

  30. UGIB • Endoscopy • best predictor of recurrent bleeding in peptic ulcer disease is the endoscopic appearance of the ulcer Risk of Recurrent Bleeding By Endoscopic Criteria Freeman et al, Gastrointest Endosc 1993

  31. UGIB • Endoscopy Clean based ulcer Adherent clot

  32. UGIB • Endoscopy Small ulcer with a prominent visible vessel 2 cm ulcer with pulsatile, arterial bleed

  33. UGIB • Endoscopy • Laine et al (Gastro 1992) showed that patients with a clean based ulcer had only a 2% risk of recurrent bleeding and could be safely fed and immediately discharged from hospital • reduces hospital stay → reduces healthcare costs • Lee et al (Gastrointest Endosc 1999) showed that “endoscopic triage” significantly decreased costs and resulted in median savings of $2068

  34. UGIB • Endoscopic Management • several endoscopic therapeutic techniques available to attempt hemostasis in patients with UGIB • Thermal • Heater Probe • Multipolar electrocautery (MPEC)/bipolar electrocautery • Argon plasma coagulation • Injection • Epinephrine • Alcohol • Ethanolamine • Other • Mechanical • Band Ligation • Hemoclips (Endoclip) • Detachable Snare (Endoloop)

  35. UGIB • Endoscopic Management • several endoscopic therapeutic techniques available to attempt hemostasis in patients with UGIB • Thermal • Heater Probe • Multipolar electrocautery (MPEC)/bipolar electrocautery • Argon plasma coagulation (APC) • Injection • Epinephrine • Alcohol • Ethanolamine • Other • Mechanical • Band Ligation • Hemoclips (Endoclip) • Detachable Snare (Endoloop)

  36. UGIB • Endoscopic Management – Thermal • all thermal devices generate heat • directly (heater probe) or • indirectly by tissue absorption of light energy (laser) or • passage of electrical current through tissue (multipolar probes, APC) • heating leads to edema, coagulation of tissue protein, contraction of vessels, resulting in hemostatic bond • multipolar electrocautery (MPEC) has been compared with sham treatment in patients with active bleeding or nonbleeding visible vessel • shown to reduce re-bleeding, emergency surgery, mean hospital stay and cost of hospitalization

  37. Thermal small ulcer with a prominent visible vessel site after eradication of the vessel using heater probe

  38. UGIB • Endoscopic Management • several endoscopic therapeutic techniques available to attempt hemostasis in patients with UGIB • Thermal • Heater Probe • Multipolar electrocautery (MPEC)/bipolar electrocautery • Argon plasma coagulation • Injection • Epinephrine • Alcohol • Ethanolamine • Other • Mechanical • Band Ligation • Hemoclips (Endoclip) • Detachable Snare (Endoloop)

  39. UGIB • Endoscopic Management – Injection • devices passed through working channel of endoscope that allow injection of liquid agents into target site of interest • injection of various solutions achieves hemostasis by mechanical tamponade • in sham controlled trials, injection therapy reduced rebleeding, transfusion requirement, emergency surgery and hospital stay Nelson et al, Gastointest Endosc 1999; Chung et al, Br Med J 1988

  40. UGIB • Endoscopic Management • several endoscopic therapeutic techniques available to attempt hemostasis in patients with UGIB • Thermal • Heater Probe • Multipolar electrocautery (MPEC)/bipolar electrocautery • Argon plasma coagulation • Injection • Epinephrine • Alcohol • Ethanolamine • Other • Mechanical • Band Ligation • Hemoclips (Endoclip) • Detachable Snare (Endoloop)

  41. UGIB • Endoscopic Management – Mechanical • Band ligation • preloaded elastic band(s) with a release mechanism affixed to tip of endoscope • esophageal variceal band ligation effective in control of active hemorrhage in 86 to 91% • Hemoclips • preloaded metal clips deployed through biopsy channel of scope (mechanism of hemostasis is mechanical compression) • achieved hemostasis in 84 to 100% of patients with variety of UGIB sources • Detachable Snares • loop placed around target tissue and loop tightened and then released • were developed to prevent and treat post-polypectomy bleeding Laine et al, Ann Intern Med 1995; Binmoeller et al, Endoscopy 1993

  42. Band ligation Esophageal varices in a 74 year-old man with alcoholic cirrhosis Two neighboring esophageal varices which have been successfully banded In another day or two the banded areas will sloughed off

  43. Detachable Snares

  44. Detachable Snares

  45. Hemoclips Erythematous ulcer base with a visible vessel Two hemostatic clips were successful applied to the vessel, and there was no further bleeding

  46. ALGORITHM TO UGIB

  47. ALGORITHM TO UGIB

  48. Summary • LGIB • resuscitation, hemodynamic stability a priority • colonoscopy procedure of choice for evaluation of acute LGIB • upper endoscopy should be performed when an upper source is suspected or when evaluation of colon is negative • if colonoscopy and upper endoscopy are negative, evaluation of small bowel should be considered • angiogram and/or a bleeding scan may be appropriate in the setting of massive bleeding • pre-operative localization of bleeding attempted prior to surgical intervention

  49. Summary • UGIB • resuscitation, hemodynamic stability a priority • determine if (based on available information), if variceal vs non-variceal UGIB • upper endoscopy procedure of choice for evaluation of UGIB • “endoscopic triage” • endoscopic therapeutic options (thermal, injection, mechanical) • use of IV proton pump inhibitors (eg. Prevacid or protonix) in the high risk group of significant benefit in reducing recurrent bleeding

More Related